1998
Contribution of advanced glycosylation to the amyloidogenicity of islet amyloid polypeptide
Kapurniotu A, Bernhagen J, Greenfield N, Al‐Abed Y, Teichberg S, Frank R, Voelter W, Bucala R. Contribution of advanced glycosylation to the amyloidogenicity of islet amyloid polypeptide. The FEBS Journal 1998, 251: 208-216. PMID: 9492286, DOI: 10.1046/j.1432-1327.1998.2510208.x.Peer-Reviewed Original ResearchConceptsAmyloid formationIslet amyloid polypeptidePre-formed aggregatesAdvanced glycosylation end productsIAPP amyloid formationAlzheimer's disease amyloid peptideCircular dichroism spectropolarimetryNucleation-dependent polymerization mechanismBeta-sheet conformationIAPP aggregationBiophysical techniquesIAPP aggregatesHigh molecular massFormation of amyloidAmyloid structuresGreen-gold birefringenceProtein amino groupsCharacteristic fibrillar structureIslet amyloid formationSeedsFibrillar amyloid structuresGlycosylationPolymerization mechanismNon-enzymatic additionPeptide aggregation
1995
Advanced glycosylation end products in diabetic renal and vascular disease
Bucala R, Vlassara H. Advanced glycosylation end products in diabetic renal and vascular disease. American Journal Of Kidney Diseases 1995, 26: 875-888. PMID: 7503061, DOI: 10.1016/0272-6386(95)90051-9.Peer-Reviewed Original ResearchConceptsAdvanced glycosylation end productsGlycosylation end productsPhase II/III clinical trialsNormal renal functionInactivate nitric oxideSpecific therapeutic modalitiesRenal functionVascular complicationsDiabetic nephropathyGlomerular sclerosisGlucose-derived Amadori productsEtiologic roleVascular diseaseClinical trialsMatrix protein synthesisTherapeutic modalitiesVascular permeabilityAdvanced glycosylationLipoprotein depositionEnd productsTissue toxicityNitric oxidePharmacologic inhibitorsToxicityProtein synthesisFormation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes
Beisswenger P, Makita Z, Curphey T, Moore L, Jean S, Brinck-Johnsen T, Bucala R, Vlassara H. Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 1995, 44: 824-829. DOI: 10.2337/diabetes.44.7.824.Peer-Reviewed Original ResearchAdvanced glycosylation end productsGlycosylation end productsRetinal diseasesEarly manifestationEnd productsDiabetesDiseaseFormation of Immunochemical Advanced Glycosylation End Products Precedes and Correlates With Early Manifestations of Renal and Retinal Disease in Diabetes
Beisswenger P, Makita Z, Curphey T, Moore L, Jean S, Brinck-Johnsen T, Bucala R, Vlassara H. Formation of Immunochemical Advanced Glycosylation End Products Precedes and Correlates With Early Manifestations of Renal and Retinal Disease in Diabetes. Diabetes 1995, 44: 824-829. PMID: 7789650, DOI: 10.2337/diab.44.7.824.Peer-Reviewed Original ResearchConceptsAdvanced glycosylation end productsEnzyme-linked immunosorbent assayAlbumin excretionDuration of diabetesElevated levelsNormal renal statusTissue advanced glycosylation end productsDiabetic vascular complicationsTissue AGE levelsGlycosylation end productsEvident retinopathyMicroalbuminuric phaseOvert microangiopathySevere retinopathyVascular complicationsDiabetic nephropathyRenal statusUrinary albuminProliferative retinopathyEarly retinopathyHigher age levelsSignificant elevationRetinopathyRetinal diseasesEarly manifestationIdentification of the Major Site of Apolipoprotein B Modification by Advanced Glycosylation End Products Blocking Uptake by the Low Density Lipoprotein Receptor *
Bucala R, Mitchell R, Arnold K, Innerarity T, Vlassara H, Cerami A. Identification of the Major Site of Apolipoprotein B Modification by Advanced Glycosylation End Products Blocking Uptake by the Low Density Lipoprotein Receptor *. Journal Of Biological Chemistry 1995, 270: 10828-10832. PMID: 7738020, DOI: 10.1074/jbc.270.18.10828.Peer-Reviewed Original ResearchConceptsLow-density lipoproteinAGE-modified formAdvanced glycosylation end productsLDL receptorApolipoprotein BHuman fibroblast LDL receptorsAGE-specific antibodiesApolipoprotein B modificationDiabetic vascular diseaseLow-density lipoprotein receptorGlycosylation end productsDensity lipoprotein receptorFibroblast LDL receptorMajor siteAGE immunoreactivityRenal insufficiencyGlucose-derived Amadori productsVascular diseasePlasma clearance kineticsDensity lipoproteinLipoprotein receptorAGE formationClearance kineticsAGE modificationPredominant siteImmunohistochemical detection of advanced glycosylation end products within the vascular lesions and glomeruli in diabetic nephropathy
Nishino T, Horii Y, Shiiki H, Yamamoto H, Makita Z, Bucala R, Dohi K. Immunohistochemical detection of advanced glycosylation end products within the vascular lesions and glomeruli in diabetic nephropathy. Human Pathology 1995, 26: 308-313. PMID: 7890283, DOI: 10.1016/0046-8177(95)90063-2.Peer-Reviewed Original ResearchConceptsAdvanced glycosylation end productsGlycosylation end productsSevere diffuse lesionsAnti-AGE antibodyComplications of diabetesInner elastic layerRenal complicationsDiabetic nephropathyAGE antibodyDiffuse lesionsNondiabetic individualsVascular lesionsPathogenic roleAGE accumulationHyaline depositsImmunohistochemical stainingPositive stainingImmunohistochemical detectionAdvanced glycosylationVascular intimaNormal agingSpecific antibodiesTissue distributionEnd productsAntibodies
1992
Hemoglobin-AGE: A Circulating Marker of Advanced Glycosylation
Makita Z, Vlassara H, Rayfield E, Cartwright K, Friedman E, Rodby R, Cerami A, Bucala R. Hemoglobin-AGE: A Circulating Marker of Advanced Glycosylation. Science 1992, 258: 651-653. PMID: 1411574, DOI: 10.1126/science.1411574.Peer-Reviewed Original ResearchConceptsAdvanced glycosylation end productsAdvanced glycosylationAGE-modified formAGE-specific antibodiesComplications of agingDiabetes-induced hyperglycemiaAge-related complicationsGlycosylation end productsCirculating MarkersDiabetic patientsRenal diseaseGlucose-derived Amadori productsNormal individualsComplicationsPatientsTissue modificationsTissue proteinsHemoglobinAmadori productsEnd productsPercentDiabeticsHyperglycemiaAtherosclerosisDiabetes